Diagnostic Performance of PSMA|based 18F|DCFPyL PET/CT in ...

Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in ...

In the presence of low PSA level in PC patients after definitive treatment, 18 F-DCFPyL PET/CT is most beneficial in detection of disease in ...

Diagnostic Performance of 18 F-DCFPyL-PET/CT in Men ... - PubMed

Performance of 18 F-DCFPyL-PET/CT achieved the study's primary endpoint, demonstrating disease localization in the setting of negative ...

Diagnostic Performance of PSMA-based 18F-DCFPyL PET/CT in ...

Sites of involvement on positive 18F-DCFPyL PET/CTs were prostate bed, pelvic lymph nodes, bone, chest and supraclavicular lymph nodes, lung, ...

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with ...

These clinical decisions are generally made at low PSA values, when standard imaging performs poorly at demonstrating disease. Prostate-specific membrane ...

Diagnostic performance of 18 F‑DCFPyL PET vs. 68 Ga‑PSMA PET ...

Based on the results, 18F-DCFPyL PET demonstrated a pooled sensitivity, specificity and AUC of 0.92, 0.59 and 0.92, respectively. 68Ga-PSMA PET/ ...

Diagnostic Performance of PSMA-based 18F-DCFPyL PET/CT in ...

Diagnostic Performance of PSMA-based 18F-DCFPyL PET/CT in Prostate Cancer Patients after Definitive Treatment with PSA Level ≤ 0.2 ng/ml · Article · Figures & ...

The diagnostic performance of 18 F-DCFPyL PET in patients with ...

Conclusions: 18F-DCFPyL PSMA PET has a strong predictive value for primary prostate cancer and is an effective method for the non-invasive diagnosis of prostate ...

Diagnostic performance of 18F-PSMA-1007 PET/CT in ... - Nature

18F-PSMA-1007 PET/CT shows relatively high detection rate in patients with PCa after radical treatment and low, rising PSA levels.

Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of ...

Recently, PSMA-targeted positron emission tomography/computed tomography (PET/CT) is increasingly used in PCa diagnostics (13, 14). Moreover, ...

A phase III, multicenter study to assess the diagnostic performance ...

A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer ...

Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on ...

The secondary endpoint, impact of PyL-PET/CT on clinical management of pts was based on the treating physician's documented clinical plans ...

A Phase 2/3 Prospective Multicenter Study of the Diagnostic ...

In cohort A, 18F-DCFPyL-PET/CT demonstrated improved diagnostic performance over conventional imaging modalities with comparable sensitivity (∼ ...

Diagnostic Accuracy of 18F-Prostate Specific Membrane Antigen ...

There was a lack of data on dose, adverse events and evidence directly comparing 18F-PSMA PET/CT to other imaging modalities. Evidence with ...

18F-DCFPyL PET/CT for Initially Diagnosed and Biochemically ...

PSMA-targeting imaging agents have been developed as valuable diagnostic agents for patients with prostate cancer (2). ... DCFPyL was successful ...

Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with ...

The disease detection rate was 59% to 66% (at least one lesion detected per patient by 18F-DCFPyL-PET/CT by central readers). Conclusions: Performance of 18F- ...

The differential diagnostic value of dual-phase 18F-DCFPyL PET/CT ...

Binding of 18F-DCFPyL at prostate cancer (PC) cells increases over time. The dual-phase protocol may be helpful in separating benign lesions ...

Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in ...

18 F-DCFPyL PET/CT is most beneficial in detection of disease in patients with GS of 8 or higher at the time of diagnosis, and the ones who have history of ADT ...

PSMA-1007PET/CT in patients with biochemical recurrence after ...

The use of (18F)-PSMA-1007 PET has been reported to have high detection efficiency in biochemical recurrence of prostate cancer after radical prostatectomy [19] ...

Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with ...

Conclusion. 18F-PSMA-1007 PET/CT can detect recurrent PCa in a high percentage of patients with biochemical relapse. The probability of a ...

Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in ...

Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in Prostate Cancer Patients After Definitive Treatment With PSA Level =0.2 ng/mL.